Omeprazole in Pregnancy: Safety Data, Risks, and Clinical Guidance
Omeprazole (PPI) is categorized as FDA Pregnancy Category C (older) / no category (new labeling). Human data are reassuring but limited.
Available Evidence
- Cohort studies (Scandinavian registries, >5000 exposures): No increased risk of major congenital malformations overall or cardiac defects specifically with first-trimester use.
- Meta-analyses: No significant association with malformations, miscarriage, preterm birth, or low birth weight.
- Animal data: High-dose omeprazole in rats caused embryo-fetal toxicity (reduced weight, skeletal variations) at maternally toxic doses. No teratogenicity at human-relevant exposures.
Clinical Recommendations
- First-line for GERD in pregnancy: Lifestyle (head elevation, small meals, avoid triggers), then antacids/alginates, then sucralfate.
- If inadequate: H2 blockers (famotidine, ranitidine — though ranitidine withdrawn) preferred before PPIs due to longer safety track record.
- PPI indication: Erosive esophagitis, Barrett's, refractory symptoms. Omeprazole 20 mg daily is standard.
- Breastfeeding: Low milk transfer (<0.1% dose); considered compatible (AAP).
Key Points
Do not stop PPI abruptly if indicated — rebound hypersecretion worsens symptoms. Discuss risk-benefit with OB/GYN. Untreated severe GERD risks aspiration, malnutrition, esophageal damage.
Pregnancy & Health - Related Articles
- Duac Cream (Clindamycin/Adapalene) in Pregnancy: Safety Assessment
- Vaccines During Pregnancy: Safety, Benefits, and Recommendations
- Alcohol During Pregnancy: Risks, FASD, and Zero-Alcohol Recommendation
- Late Period with Negative Pregnancy Tests: Common Causes
- Sunny D During Pregnancy: Safety, Sugar Content & Better Alternatives
- Early Pregnancy Detection: How Soon Can a Doctor Confirm Pregnancy?
- Bleeding After Positive Pregnancy Tests: Causes and Next Steps
